Seegene, Inc. ("Seegene"), a global leader in molecular diagnostics, announced today that its U.S. subsidiary, Seegene USA, Inc. ("Seegene USA"), has received an Emergency Use Authorization (EUA) from ...

Got a stuffy nose and a cough? If you go to an urgent care or ER, chances are that you may be able find out exactly what type of germ is making you sick, thanks to newer tests that don’t look for just ...

The U.S. Multiplex Assays Market is projected to grow from USD 1.12 Billion in 2025 to USD 2.65 Billion by 2035, while Europe ...

In the article accompanying this editorial, Gray et al 4 present the results of a survey of practicing oncologists at the Dana-Farber Cancer Institute (DFCI) that was conducted before the roll-out of ...

Fast and easy-to-use respiratory PCR test comes onto market as flu season gains pace in Northern Hemisphere CE-IVD marking in Europe granted for NeuMoDx™ Flu A-B/RSV/SARS-CoV-2 Vantage Test, has also ...

Multiplex gene testing may not bring about unnecessary surgery or adverse psychological effects, according to findings from a recent study. Interim analysis of a clinical trial of multiplex gene ...

Multiplex genetic testing, including both moderate- and high-penetrance genes for cancer susceptibility, is associated with greater uncertainty than traditional testing, presenting challenges to ...

Please provide your email address to receive an email when new articles are posted on . “Contrary to the initial intentions of the multiplex assay, our study demonstrates that the inherent advantages ...

DUBLIN--(BUSINESS WIRE)--The "Syndromic Multiplex Diagnostic Markets - Strategies and Trends, Forecasts by Syndrome (Respiratory, Sepsis, GI etc.) & by Country - With Market Analysis, Executive Guides ...

GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the European launch of the NeuMoDx™ Flu A-B/RSV/SARS-CoV-2 Vantage Test that ...